![]() | A major contributor to this article appears to have a
close connection with its subject. (April 2024) |
Flemming Ørnskov | |
---|---|
![]() | |
Born | 1957 or 1958 (age 65–66) [1] |
Nationality | Danish |
Alma mater |
University of Copenhagen INSEAD Harvard University |
Occupation(s) | CEO, Galderma |
Flemming Ørnskov (born 1957/58) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma [2] since October 2019.
He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel. [3] He previously worked for Bayer, Bausch & Lomb and Novartis. [2]
He is also the non-executive chairman of Waters Corporation, a position he's been holding since 2017. [4] [5]
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University. [1]
Ørnskov led Galderma's IPO on the Zurich stock exchange on March 22, 2024, one of the biggest offerings in Europe in years and the biggest in Switzerland since 2017. [6] [7] He declares Galderma plans to use the proceeds to pay down debt and invest in its pipeline. [8]
Top 100 Best-Performing CEOs in the World, 2015 - Harvard Business Review [9]
Top 25 Most Influential People in Biopharma Today, 2013 - Fierce Biotech [10]
![]() | A major contributor to this article appears to have a
close connection with its subject. (April 2024) |
Flemming Ørnskov | |
---|---|
![]() | |
Born | 1957 or 1958 (age 65–66) [1] |
Nationality | Danish |
Alma mater |
University of Copenhagen INSEAD Harvard University |
Occupation(s) | CEO, Galderma |
Flemming Ørnskov (born 1957/58) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma [2] since October 2019.
He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel. [3] He previously worked for Bayer, Bausch & Lomb and Novartis. [2]
He is also the non-executive chairman of Waters Corporation, a position he's been holding since 2017. [4] [5]
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University. [1]
Ørnskov led Galderma's IPO on the Zurich stock exchange on March 22, 2024, one of the biggest offerings in Europe in years and the biggest in Switzerland since 2017. [6] [7] He declares Galderma plans to use the proceeds to pay down debt and invest in its pipeline. [8]
Top 100 Best-Performing CEOs in the World, 2015 - Harvard Business Review [9]
Top 25 Most Influential People in Biopharma Today, 2013 - Fierce Biotech [10]